LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.

scientific article published on 2 December 2016

LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/MDS.26892
P698PubMed publication ID27911006

P50authorJanice HoltonQ30089851
Glenda HallidayQ45304807
Nicolas DzamkoQ57321778
Wilma van de BergQ57421896
Rina BandopadhyayQ106926125
P2093author name stringShigeo Murayama
Marc F Bolliger
Ye Zhao
Junko Takahashi-Fujigasaki
Masaki Takao
Akiko Uchino
R Jeremy Nichols
Amanda M Gysbers
Sandrine Wauters
P2860cites workParkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activityQ22254785
LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell modelsQ24304959
LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative studyQ24307455
Localization of LRRK2 to membranous and vesicular structures in mammalian brainQ24318643
Interplay of LRRK2 with chaperone-mediated autophagyQ24322747
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localizationQ24339094
Genome-wide association study reveals genetic risk underlying Parkinson's diseaseQ24646654
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathologyQ28131833
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's diseaseQ28292932
The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signalingQ28480459
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's diseaseQ29614900
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyQ29614953
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activityQ29615144
Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagyQ33920691
Arsenite stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich repeat kinase 2 (LRRK2), promoting self-association and cellular redistributionQ33985278
An emerging role for LRRK2 in the immune systemQ34300438
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Q35780973
Large-scale replication and heterogeneity in Parkinson disease genetic lociQ36149955
LRRK2 inhibition attenuates microglial inflammatory responsesQ36493605
MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.Q36525872
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localizationQ36780383
Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodiesQ36929535
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteriaQ37631959
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?Q38198207
Neuropathology of α-synuclein propagation and braak hypothesisQ38580816
LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's diseaseQ39432630
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibitionQ39457004
LRRK2 dephosphorylation increases its ubiquitinationQ41785779
Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brainQ48162781
Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brainQ48372083
Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.Q54529101
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectParkinson's diseaseQ11085
phosphorylationQ242736
P304page(s)423-432
P577publication date2016-12-02
P1433published inMovement DisordersQ1486418
P1476titleLRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies
P478volume32

Reverse relations

cites work (P2860)
Q89484985An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts
Q61849485Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology
Q47139369Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers
Q90375075GTP-binding inhibitors increase LRRK2-linked ubiquitination and Lewy body-like inclusions
Q96953324LRRK2 Phosphorylation, More Than an Epiphenomenon
Q90638116Leucine Rich Repeat Kinase 2 and Innate Immunity
Q54978235Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo.
Q64759312Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders
Q59797902Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice
Q47281413Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers
Q39263032Targeting LRRK2 in Parkinson's disease: an update on recent developments
Q55442883The Enzymatic Core of the Parkinson’s Disease-Associated Protein LRRK2 Impairs Mitochondrial Biogenesis in Aging Yeast.
Q64811522The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors

Search more.